Clinical trials: Neoplasms Recurrence
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Recurrent Ependymoma
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain.
- Trial name
- 5-AZA (NCT03572530)
- Testing
- 5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Myeloid Leukemia, Relapsed, Adult
CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia
- Trial name
- NCT03985007
- Testing
- CDIAG regimen
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the…
- Trial name
- NCT02438995
- Testing
- Intraarterial Cetxuimab (Erbitux)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwell Health
Leukemia
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00840177
- Testing
- cytarabine, idarubicin, pravastatin sodium
- Where
- 185 sites in United States
- Volunteers
- 115 people
- Sponsor
- SWOG Cancer Research Network
Solid Tumor, Miscellaneous
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
Alterations in the fibroblast growth factor receptor (FGFR) gene are involved in the development of cancer. These anomalies are found at very variable frequencies (from less than 1% to around 10%) in cancers of the bile ducts…
- Trial name
- AcSé PEMI (NCT06653777)
- Testing
- Pemigatinib
- Where
- 6 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05126719
- Testing
- MRG003, Capecitabine tablets, Docetaxel injection
- Where
- 23 sites in China
- Volunteers
- 238 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Endometrial Adenoacanthoma, Endometrial Adenocarcinoma
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor
- Conditions
- Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma
- Trial name
- NCT00025467
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07025564
- Testing
- Biospecimen Collection, Echocardiography Test, miR-126 Inhibitor miRisten
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Brachytherapy in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Radiation therapy uses high-energy radiation to damage tumor cells. Brachytherapy uses radioactive material that is placed directly into or near the tumor. Brachytherapy may kill more tumor cells.
- Trial name
- NCT00005939
- Testing
- brachytherapy, phosphorus P32
- Where
- United States
- Sponsor
- Center for Molecular Medicine
Melanoma (Skin)
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or…
- Trial name
- NCT00053781
- Testing
- perifosine
- Where
- 6 sites in Canada
- Volunteers
- 18 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Neoplasm
Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer
The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.
- Trial name
- NCT00677144
- Testing
- OS (oxalipaltin+S-1), XELOX (oxalipaltin+capecitabine)
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- Hallym University Medical Center
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Glioblastoma, GBM
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection.
- Conditions
- Glioblastoma, GBM, Glioma
- Trial name
- NCT04391595
- Testing
- Abemaciclib, LY3214996
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Nader Sanai
Recurrent Breast Cancer
A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer
The purpose of this study is to evaluate the response rate in patients with taxane-pretreated recurrent breast cancer receiving paclitaxel loaded polymeric micelle (Genexol-PM).
- Trial name
- NCT00912639
- Testing
- Paclitaxel loaded Polymeric micelle
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Korean Breast Cancer Study Group
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
This randomized phase II trial studies how well giving rasburicase together with allopurinol works in treating patients with hematologic malignancies. Rasburicase may reduce the level of uric acid in the blood.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01564277
- Testing
- rasburicase, allopurinol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.
- Trial name
- NCT02456675
- Testing
- INCB040093 Monotherapy, INCB040093, itacitinib
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Cervical Cancer, Recurrent
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
This is a Phase II clinical trial to evaluate the safety and efficacy of Utidelone, a genetically engineered epothilone derivative, combined with Toripalimab, a PD-1 inhibitor, in patients with recurrent or metastatic cervical…
- Conditions
- Cervical Cancer, Recurrent, Metastatic
- Trial name
- NCT07363330
- Testing
- Utidelone plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Zhongnan Hospital
Platinum-resistant Recurrent Ovarian Cancer
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT04720807
- Testing
- Letrozole combined with anlotinib hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or…
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody
- Trial name
- NCT04188860
- Testing
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Lei Li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.